Linkster Therapeutics AG develops novel therapeutic antibodies using our proprietary Flycode® and Sybody® platforms. Our technologies screen antibody properties in high throughput in vivo, thus enabling precise tissue targeting beyond trivial molecular recognition and massively reduce animal trials.

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2019
  • Number of employees in Switzerland
    1-9
Key business